Company Profile
Ensysce Biosciences Stock Price, News & Catalysts
- Ticker:
- ENSC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.38 USD (-5.83%)
Close
Last updated: August 17, 2026
3.84M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, ENSC closed down 5.83% at $0.3766. No new same-company headline was identified in the current news window.
Company overview
Complex-Pain Therapeutics
Ensysce Biosciences develops neuroplastogenic and opioid-based therapies for severe and complex pain. The company expanded its strategy through the acquisition of Cy Biopharma.
CY200
CY200 is an orphan-designated neuroplastogenic candidate for complex regional pain syndrome type 1. It is designed to address the underlying neurobiology of the disorder rather than only managing symptoms.
Protected Opioid Platform
Ensysce's Trypsin-Activated Abuse Protection technology keeps opioid prodrugs inactive until they reach the small intestine. PF614 applies this approach to an extended-release oxycodone product.
Overdose-Protection Program
PF614-MPAR combines abuse protection with Multi-Pill Abuse Resistance technology intended to limit oral overdose. The program has received FDA Breakthrough Therapy designation.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Ensysce Biosciences (ENSC)?
Ensysce Biosciences (ENSC) most recently closed at 0.38 USD, a -5.83% move versus the previous session.
What is the market cap of Ensysce Biosciences (ENSC)?
Ensysce Biosciences currently has a market capitalization of 3.84M USD on BioPharmSignal.
What does Ensysce Biosciences do?
Complex-Pain Therapeutics Ensysce Biosciences develops neuroplastogenic and opioid-based therapies for severe and complex pain. The company expanded its strategy through the acquisition of Cy Biopharma. CY200 CY200 is an orphan-designated neuroplastogenic candidate for complex regional pain syndrome type 1. It is designed to address the underlying...
On which exchange is ENSC stock listed?
Ensysce Biosciences (ENSC) is associated with NASDAQ, United States, Biopharma.
What is Complex-Pain?
Complex-Pain Therapeutics Ensysce Biosciences develops neuroplastogenic and opioid-based therapies for severe and complex pain.
Which conditions is Ensysce Biosciences targeting with Complex-Pain?
Complex-Pain Therapeutics Ensysce Biosciences develops neuroplastogenic and opioid-based therapies for severe and complex pain. The company expanded its strategy through the acquisition of Cy Biopharma. CY200 CY200 is an orphan-designated neuroplastogenic candidate for complex regional pain syndrome type 1. It is designed to address the underlying...
What is Therapeutics?
Complex-Pain Therapeutics Ensysce Biosciences develops neuroplastogenic and opioid-based therapies for severe and complex pain.
What is Ensysce?
Complex-Pain Therapeutics Ensysce Biosciences develops neuroplastogenic and opioid-based therapies for severe and complex pain.